Volume 2.01 | Jan 14

Prostate Cell News 2.01, January 14, 2011.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

miR-99 Family of microRNAs Suppresses the Expression of Prostate Specific Antigen and Prostate Cancer Cell Proliferation 
MicroRNAs (miRNAs) have been globally profiled in cancers but there tends to be poor agreement between studies including in the same cancers. Additionally, few putative miRNA targets have been validated. To overcome the lack of reproducibility, scientists profiled miRNAs by next generation sequencing and locked nucleic acid miRNA microarrays, and verified concordant changes by quantitative RT-PCR. [Cancer Res]

ProstaCult_v04_645x110-ThanWith



SPECIAL FEATURE

Facebook Cell Therapy News is now on Facebook. Join us! 

Twitter Follow us on Twitter! @ProstateCell

Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]



SCIENCE NEWS

First Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate Cancer
Accuray Incorporated announced the first published five-year outcomes on low risk prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System. [Press release from Accuray Incorporated discussing online prepublication in Radiation Oncology]

Scientists Now Know Why Some Cancers Become Malignant and Others Don’t
Cancer cells reproduce by dividing in two, but a molecule known as PML limits how many times this can happen, according to researchers. [Press release from the University of Montreal discussing online prepublication in Genes and Development]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies
 
 
WATCH THE VIDEO STEMCELL Technologies Inc
 




CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Regulation of E2Fs and Senescence by PML Nuclear Bodies
Scientists show that the mechanism by which promyelocytic leukemia protein (PML) induces a permanent cell cycle exit and activates p53 and senescence involves a recruitment of E2F transcription factors bound to their promoters and the retinoblastoma proteins to PML nuclear bodies enriched in heterochromatin proteins and protein phosphatase 1-alpha. [Genes Dev]

microRNA-616 Induces Androgen-Independent Growth of Prostate Cancer Cells by Suppressing Expression of Tissue Factor Pathway Inhibitor TFPI-2
Investigators report a functional impact in prostate cancer cells for overexpression of the microRNA miR-616, which occurred consistently in cells that were androgen-independent versus androgen-dependent. [Cancer Res]

Decreased Expression and Androgen Regulation of the Tumor Suppressor Gene INPP4B in Prostate Cancer
Investigators discovered that the androgen receptor induces the expression of the tumor suppressor inositol polyphosphate 4-phosphatase type II (INPP4B) but not PTEN in prostate cancer cells. [Cancer Res]

LIM Kinase 1 Modulates Function of Membrane Type Matrix Metalloproteinase 1: Implication in Invasion of Prostate Cancer Cells
The purpose of this study is to determine any functional relation between LIM kinase 1 and membrane type matrix metalloproteinase 1 and its implication in cell invasion. [Mol Cancer]

Inhibition of Tumor Growth and Sensitization to Chemotherapy by RNA Interference Targeting Interleukin-6 in the Androgen-Independent Human Prostate Cancer PC3 Model
The objective of this study is to investigate the inhibitory effects of interleukin-6 secretion by androgen-independent human prostate cancer PC3 cells on their growth and chemosensitivity. [Cancer Sci]

Induction of Autophagy-Dependent Apoptosis by the Survivin Suppressant YM155 in Prostate Cancer Cells
Researchers demonstrated that YM155, a novel survivin suppressant, induced both apoptosis, and autophagy that was shown by conversion of cytosolic-associated protein light chain 3 into autophagosome-associated form and a punctate fluorescence pattern of an ectopic GFP-LC3 protein. [Cancer Lett]

Arachidonate 12-Lipoxygenase May Serve as a Potential Marker and Therapeutic Target for Prostate Cancer Stem Cells
Researchers examined the expression of arachidonate 12-lipoxygenase in prostate cancer stem cells (PCa SCs) to test if it can serve as a unique marker and therapeutic target for PCa SCs. [Int J Oncol]

Use of 1,25-Alpha Dihydroxyvitamin D3 as a Cryosensitizing Agent in a Murine Prostate Cancer Model
Scientists investigated the use of a non-toxic adjunctive agent, vitamin D3, with cryotherapy to sensitize prostate cancer to low temperature-induced, non-ice rupture-related cell death. [Prostate Cancer Prostatic Dis]

CLINICAL RESEARCH

Comparison of Qualitative and Quantitative Approach to Prostate MR Spectroscopy in Peripheral Zone Cancer Detection
The objective of this study is to compare the diagnostic performance of a qualitative (pattern recognition) and a quantitative (numerical assessment) approach to magnetic resonance spectroscopy (MRS) in the diagnosis of peripheral zone prostate cancer. [Eur J Radiol]

Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: Five-Year Outcomes
Scientists present the outcomes for low-risk prostate cancer patients with a median follow-up of 5 years after stereotactic body radiotherapy. [Radiat Oncol]

ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program
The objective of the study was to assess a novel application of the Prostate Health Index and biopsy tissue DNA content in benign-adjacent and cancer areas to predict which patients would eventually require treatment of prostate cancer in the Proactive Surveillance cohort. [Urology]




INDUSTRY NEWS

Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
Dendreon Corporation announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline. [Dendreon Corporation Press Release]

Enzon to Begin Phase I Study of Novel Androgen Receptor mRNA Antagonist in Castration-Resistant Prostate Cancer
Enzon Pharmaceuticals, Inc. announced the Investigational New Drug approval by the US Food and Drug Administration and plan to commence enrollment into a Phase Ia/Ib study shortly. [Enzon Pharmaceuticals, Inc. Press Release]

BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014
BIND Biosciences announced that it has initiated a Phase I clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. [BIND Biosciences Press Release]

$1 Million Dollar Prostate Cancer Foundation Opportunity
These two-year awards will provide a total of $1 million per team. This round of awards will focus on funding Treatment Science: studies of new ideas in man or laboratory support of a high impact clinical investigation. [Dana-Farber/Harvard Cancer Center Press Release]







Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us